PTO/SB/21 (0 lease type a plus sign (+) inside this box -> [+] Approved for use through 10/31/2002. OMB 0651-003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 09/869,003 TRANSMITTAL **Filing Date** September 25, 2001 **FORM** First Named Invent r SCALA, Giuseppe DEC 🛭 0 2002 (to be used for all correspondence after initial filing) 1648 Group Art Unit TECH CENTER 1600/2900 Jeffrey J. Stucker **Examiner Name** Total Number of Pages in This Submission **Attorney Docket Number** 015280-386200US ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers Fee Transmittal Form-in duplicate (for an Application) Group Appeal Communication to Board of Fee Attached ☐ Drawing(s) Appeals and Interferences Appeal Communication to Group Amendment / Reply-"Response to Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Restriction Requirement" Petition Proprietary Information After Final Petition to Convert to a Affidavits/declaration(s) Status Letter Provisional Application Power of Attorney, Revocation Extension of Time Request-2 mos. Other Enclosure(s) Change of Correspondence Address (please identify below): per accompanying Fee Transmittal Terminal Disclaimer Return Postcard Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) The Commissioner is authorized to charge any additional fees to Certified Copy of Priority Deposit Account 20-1430. Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Townsend and Townsend and Crew LLP Firm Reg. No. 44,879 Jean M. Lockyer, Ph.D. Individual name Signature Date December 12, 2002 **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 2023 Lon this date: December 12, 2002

Typed or printed name Malinda C. Dagit

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. The will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1414685 v1

App Tor use through 10/31/2002. OMB 0651-0052

Patent and Tradents Diffice: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Complete if Known				
FEE TRANSMITTAL	Application Number	09/869,003	RECEIV		
for FY 2003 Patent fees are subject to annual revision.	Filing Date	September 25, 2001	DEC 2 n 21	ED	
Patent fees are subject to annual revision.	First Named Inventor	SCALA, Giuseppe	DEC 2 0 20	02	
Applicant claims small entity status. See 37 CFR 1.27	Examiner Name	Jeffrey J. Stucker	TECH CENTER 160	0 (0	
	Group Art Unit	1648	LOU OF MIEW 180	YU/290	
TOTAL AMOUNT OF PAYMENT (\$) 400	Attorney Docket No.	015280-386200US	J	1	

METHOD OF PAYMENT (check all that apply)				FEE CA	ALCULATION (continued)	
, , , , , , , , , , , , , , , , , , , ,		ITIONAL	FEES			
Deposit Account:	Large	Entity	Small	Entity	•	
Deposit	Fee	Fee	Fee	Fee	Fee Description	Fee
Account 20-1430	Code 1051	( <b>\$)</b> 130	<b>Code</b> 2051	(\$) 65	Surcharge - late filing fee or oath	Paid
Number	1051	50	2052	25	Surcharge - late provisional filing fee	
Describe (Fig. 1)		-			or cover sheet.	
Deposit Account Townsend and Townsend and Crew LLP	1053	130	1053	130	Non-English specification	
Name ·	1812	2,520	1812	2,520	For filing a request for reexamination	
The Commissioner is authorized to: (check all that apply)		920*	1804	920*	Requesting publication of SIR prior to Examiner action	
Charge fee(s) indicated below Credit any overpayments  Charge any additional fee(s) during the pendency of this application		1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
Charge fee(s) indicated below, except for the filing fee		110	2251	55	Extension for reply within first month	· ·
to the above-identified deposit account.		400	2252	200	Extension for reply within second	400
FEE CALCULATION					month	400
1. BASIC FILING FEE	1253	920	2253	460	Extension for reply within third month	
Large Entity Small Entity	1254	1,440	2254	720	Extension for reply within fourth month	
Fee Fee Fee Fee Description Code (\$)	1255	1,960	2255	980	Extension for reply within fifth month	
Code (\$) Code (\$) Fee Paid	1401	320	2401	160	Notice of Appeal	
1002 330 2002 165 Design filing fee	1402	320	2402	160	Filing a brief in support of an appeal	
1002 330 2002 103 Design ming fee	1403	280	2403	140	Request for oral hearing	
1004 740 2004 370 Reissue filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1005 160 2005 80 Provisional filing fee	1452	110	2452	55	Petition to revive – unavoidable	
SUBTOTAL (1)	1453	1,280	2453	640	Petition to revive – unintentional	
SUBTOTAL (1)	1501	1,280	2501	640	Utility issue fee (or reissue)	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1502	460	2502	230	Design issue fee	
Fees from	1503	620	2503	310	Plant issue fee	
Extra Claims below Fee Paid	1460	130 50	1460	130 50	Petitions to the Commissioner	
Total Claims -** = X =	1807		1807		Petitions related to provisional applications	
Independent Claims =	1806	180	1806	180	Submission of Information Disclosure Stmt	
Multiple Dependent	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
Large Entity Small Entity Fee Fee Fee Fee Fee	1809	740	2809	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
Code (\$) Code (\$)	1810	740	2810	370	For each additional invention to be examined (37 CFR § 1.129(b))	
1202 18 2202 9 Claims in excess of 20 1201 84 2201 42 Independent claims in excess of 3	1801	740	2801	370	Request for Continued Examination	
1201 64 2201 42 Independent claims in excess or 3		•			(RCE)	
1204 84 2204 42 *** Reissue independent claims over original patent	1802	1802 900 1802 900 Request for expedited examination of a design application				
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	Other fee (specify)					
SUBTOTAL (2) (5)		ed by Bas	sic Filing	Fee Pai	d SUBTOTAL (3) (\$)400	
**or number previously paid, if greater; For Reissues, see above						

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)

Jean M. Lockyer, Ph.D. | Registration No. (Attorney/Agent) | 44,879 | Telephone | 415-576-0200

Signature

Date1 | 12 December 2002

WARNING Information on the term may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

DEL 18 2000 ASSESSED TO THE PROPERTY OF TRADER OF THE PROPERTY OF TRADER OF THE PROPERTY OF TH

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 015280-386200US

Client Ref. No.: E-070-99/

RECEIVE

DEC 2 0 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

n 12 Ders. 2002

TOWNSEND and TOWNSEND and CREW LLL

By: Malinda World

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCALA et al.

Application No.: 09/869,003

Filed: September 25, 2001

For: NOVEL HIV RELATED PEPTIDES

Examiner:

Jeffrey J. Stucker

Art Unit:

1648

RESPONSE TO RESTRICTION

REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Restriction Requirement mailed September 12, 2002, Applicants elect Group I, claims 1-10, drawn to an antigenic peptide. Applicants further elect SEQ ID NO:1. Enclosed herewith is a fee authorization to extend the time for response for two months.

The foregoing election is made with traverse and the groups set forth by the Examiner stem from a common concept and theory and are thus related. According to the MPEP, where claims can be examined together without undue burden, the Examiner must examine the claims on the merits even though they are directed to independent and distinct inventions. *See*, the MPEP at 803.01. In establishing that an "undue burden" would exist for co-examination of claims, the Examiner must show that examination of the claims would involve substantially different prior art searches, making the co-examination burdensome. Applicants respectfully submit that examination of the

SCALA et al.

Application No.: 09/869,003

Page 2

claims in the groups would not create an undue burden. For example, claims drawn to phagotopes and methods of using peptides can be examined together with the claims drawn to the peptides without undue burden, as a search that encompasses the sequences will also identify art related to phagotopes and the use of the peptides. Applicants therefore respectfully request withdrawal of the restriction requirement.

Further, in accordance with the Examiner's comments on page 4 of the Office Action, Applicants respectfully request rejoinder of the methods of use claims, once the product claims are determined to be allowable.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Jean M. Lockyer, Ph.D.

Reg. **M**o. 44,879

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

JML:jml SF 1414644 v1